SEC Form 10-Q filed by MeiraGTx Holdings plc
Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/31/2024 | $36.00 | Buy | Chardan Capital Markets |
4 - MeiraGTx Holdings plc (0001735438) (Issuer)
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment - Company awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for AAV8-RK-AIPL1 for the treatment of AIPL1-Leber congenital amaurosis 4 (LCA4) LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical-stage genetic medicine company, today announced financial and operational results f
LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an underwritten offering of 12,500,000 of its ordinary shares at an offering price of $4.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be $50 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx. The financing was led by Sanofi, which made a $30 million equity investment in MeiraGTx through the offering. Other participants included Perceptive Advisors and leading inst
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented in an oral session at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Received $50 million milestone following initiation of the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) - Clinical development milestones met and remain on track for the rest of the year for AAV-hAQP1 for RIX, bota-vec for XLRP, and AAV-GAD for Parkinson's disease LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a verticall
Clinically meaningful improvements in xerostomia symptoms measured by two different xerostomia PROs demonstrated across both unilaterally and bilaterally treated cohorts at 12 monthsIncreases in whole saliva flow rates observed post-treatment, providing objective evidence of biological activity, reaching the normal range in bilaterally treated participants by 2 months and persisting through the Month 12 assessmentAcross assessments, greater improvements observed in bilaterally treated participants compared to those treated unilaterally Early long-term follow-up data suggest durability of improvement to at least 3 years post-treatmentAAV2-hAQP1 appears safe and well tolerated at each dose te
LONDON and NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to present an update on the Company's AAV-hAQP1 clinical program for the treatment of grade 2/3 radiation-induced xerostomia (RIX) on Tuesday, June 27, 2023, at 8:00 a.m. ET. The presentation will include: 1) Data from the completed Phase 1 AQUAx clinical study for the 24 patients treated with AAV-hAQP1 in the unilateral and bilateral cohorts: Safety and tolerability12-month data for PRO assessments of xerostomia symptoms in the unilateral cohorts (n=12)12-month data for
Clinically meaningful improvements in xerostomia symptoms and disease burden reported in patient reported outcome (PRO) measures in both unilateral and bilateral cohortsIncreases in whole saliva flow rates were seen in both unilateral and bilateral cohorts Overall degree of improvement was greater in bilateral compared to unilateral cohorts AAV2-hAQP1 appears safe and well tolerated at each dose tested Webcast and conference call to be held today, December 13, 2022, at 8:00 a.m. ET LONDON and NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced positive clinical data from the ongoin
Chardan Capital Markets resumed coverage of MeiraGTx with a rating of Buy and set a new price target of $36.00
4 - MeiraGTx Holdings plc (0001735438) (Issuer)
3 - MeiraGTx Holdings plc (0001735438) (Issuer)
4 - MeiraGTx Holdings plc (0001735438) (Issuer)
8-K - MeiraGTx Holdings plc (0001735438) (Filer)
424B5 - MeiraGTx Holdings plc (0001735438) (Filer)
8-K - MeiraGTx Holdings plc (0001735438) (Filer)
Company cofounder and CTO to lead button battery safety tech company toward commercialization The Directors of Landsdowne Labs, LLC, are pleased to announce the appointment of Bryan Laulicht to Chief Executive Officer. Laulicht, a company cofounder, has served as Lansdowne's Chief Technology Officer since the company's formation in 2017. He has also co-founded and served in leadership positions at two other companies focused on applying biophysics and bioengineering approaches to fulfilling unmet medical and safety needs. Both of those companies have been acquired for a combined total greater than $500M. Lansdowne's technology, applied to small, coin-like "button" batteries, is design
LONDON and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced the appointment of Dr. Debra Yu to its Board of Directors. Dr. Yu currently serves as President and Chief Strategy Officer of LianBio, and previously served as LianBio's President and Chief Business Officer. Dr. Yu has more than 30 years of healthcare industry experience in business development, alliance management, investment banking and capital markets. She has held senior positions at Pfizer in its Worldwide Business Development organization and Labrador Advisors, LLC, where she advised numerous partnerships and licen
SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)
SC 13G/A - MeiraGTx Holdings plc (0001735438) (Subject)
SC 13D/A - MeiraGTx Holdings plc (0001735438) (Subject)
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Dutch Bros Inc. (NYSE:BROS). On May 7, Dutch Bros posted better-than-expected first-quarter financial results and raised its full-year revenue guidance. “The outlook is fabulous. There is a lawsuit in July that, involving formula,” Cramer said when asked about Abbott Laboratories (NYSE:ABT). “We're waiting until at least it gets to par or 100 to be able to buy more. But we believe in the company.” On April 17, Abbott Laboratories reported better-than-expected earnings for its first quarter. The company posted first-quarter sales of $9.96 billion, up 10.8% on an organic basis for the underlying base business, beatin
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.50) by 36 percent. This is a 48.39 percent increase over losses of $(0.62) per share from the same period last year. The company reported $697.00 thousand in sales this quarter. This is a 79.09 percent decrease over sales of $3.33 million the same period last year.
RBC Capital analyst Luca Issi reiterates MeiraGTx Hldgs (NASDAQ:MGTX) with a Outperform and maintains $11 price target.